Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
|Articles|February 19, 2014
Equipment and Processing Report
- Equipment and Processing Report-02-19-2014
- Volume 0
- Issue 0
Schreiner MediPharm Introduces SecuMed Labeling System
A combination of overt and covert features protects against counterfeiting.
Schreiner MediPharm’s SecuMed pharmaceutical labeling system offers authentication and protection against counterfeiting in a multi-step security concept. The SecuMed labeling system can be customized according to the specific requirements of pharmaceutical manufacturers. The labels can integrate a specific mix of overt, covert, and machine-readable security features. Options include complex holograms, ShiftSecure color-shifting ink, thermo-reactive print (in which colors change at various temperatures), and a covert feature known as LaserSecure, which involves invisible, machine-readable security pigments that can be integrated into all graphic elements and colors. The company will introduce the SecuMed labeling system to the North American market at INTERPHEX 2014.
Source:
Articles in this issue
over 12 years ago
Complying with Revised USP Chapters on Weighingover 12 years ago
Developments in Producing MicrospheresRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Trending on Pharmaceutical Technology
1
Winners of the 2026 CPHI Pharma Awards Announced
2
Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
3
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
4
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
5